ABSTRACT. A mentally retarded girl with epileptic sei-CASE REPORT zures is described. urinary organic acid screening ievealed a massive excretion of glyceric acid, a normally barely detectable metabolite. Hyperglycinemia was not observed. Capillary gas chromatography of the 0-acetylated (-)-menthyl ester of urinary glyceric acid showed the substance to have the D-configuration. The urinary D-glycerate excretion remained unaltered after an oral load with 200 mg/kg L-serine, but oral loading with fructose (1 g/kg) or dihydroxyacetone (1 g/kg) caused a sharp increase of the Dglycerate excretion. Treatment with a diet moderately restricted in fructose led to some clinical improvement as judged by subjective criteria. The metabolic lesion is thought to be located at some step of the fructose catabolic pathway, possibly at the level of hepatic triokinase deficiency. (Pediatr Res 21: 502-506, 1987) Abbreviations GAPD, glyceraldehyde-3-phosphate dehydrogenase NKH, nonketotic hyperglycinemia TMS, trimethylsilyl Hb, hemoglobin D-Glyceric acidemia seems to be an extremely rare inborn error of metabolism. To date only three isolated cases have been reported (1-3). The clinical presentation of the patients varied: the patient described by Wadman et al. (2) had a chronic metabolic acidosis and only a moderate developmental delay, whereas the patients described by Brandt et al. (I) and Grandgeorge et al. (3) showed all characteristic symptoms of NKH such as extreme hypotonia, deep mental retardation, myoclonic jerks, and grand ma1 seizures. Brandt's patient not only had the clinical signs of NKH, but actually had elevated levels of glycine in his plasma and urine. The concentration of D-glycerate in urine of the previously described patients ranged from 1-1 16 mmol/liter.
D-Glyceric acidemia seems to be an extremely rare inborn error of metabolism. To date only three isolated cases have been reported (1) (2) (3) . The clinical presentation of the patients varied: the patient described by Wadman et al. (2) had a chronic metabolic acidosis and only a moderate developmental delay, whereas the patients described by Brandt et al. (I) and Grandgeorge et al. (3) showed all characteristic symptoms of NKH such as extreme hypotonia, deep mental retardation, myoclonic jerks, and grand ma1 seizures. Brandt's patient not only had the clinical signs of NKH, but actually had elevated levels of glycine in his plasma and urine. The concentration of D-glycerate in urine of the previously described patients ranged from 1-1 16 mmol/liter.
A clear-cut enzyme defect leading to D-glyceric acidemia has not yet been found, although K$lvraa et al. (4) found evidence for a decreased activity of D-glycerate dehydrogenase in the fresh leukocytes of Brandt's patient. Enzyme studies were not performed in the other two patients.
Herein we describe a patient with ~-glyceric acidemia. Results of biochemical investigations as well as of clinical studies, designed to obtain more insight in the metabolic defect, will be given.
The proband B., the first child of healthy, nonrelated parents, was born at home after an uneventful gestation of 38 wk; her birth weight was 2800 g. There were signs of perinatal asphyxia: crying started late. Apgar scores were not recorded. The mother's next pregnancy ended with a spontaneous abortion at 1 1 wk; the third pregnancy resulted in the birth of a child with spina bifida who died in the neonatal period. Subsequently two healthy children were born.
In the first weeks of life the patient was noted to be hypotonic and she had severe feeding difficulties. Motor development was slow: she could only sit without support at the age of 18 months. At the age of 12 months she had her first seizure located at the right half of the body during a febrile period. Recurrent seizures were noticed during the following week. Thereafter a right-sided spastic hemiplegia was observed. Two kinds of seizures became manifest: adveriive fits as well as focal seizures at the right part of the body. Psychomotor development appeared to be severely retarded.
At the age of 5% yr she was referred for evaluation; the parents asked for genetic advice. On admission her body weight was on the 10th percentile, her length on the 50th percentile, and her skull circumference on the 75th percentile. She was brachycephalic, had a telecanthus, a depressed nose bridge, and low implanted ears. Her dental gums were hypertrophic, whereas her arms and hands showed signs of automutilation. She also had attacks of aggressive behavior (i.e. biting and shouting) especially toward the parents. Neurologically there was still a right-sided hemiplegia. Her epilepsy was treated with diphantoin 225 mg, valproate 900 mg, and clonazepam 0.6 mg daily.
Laboratory investigations. None of the routine clinical chemical determinations revealed abnormalities. Anemia was not observed. A broad screening for inborn errors of metabolism including the chromatographic analysis of amino acids, organic acids, purines and pyrimidines, mono-, di-, and oligosaccharides, acid mucopolysaccharides, phenolic acids, and imidazoles was carried out. This revealed an abnormal glyceric aciduria.
MATERIALS AND METHODS
Urinary organic acid screening was done by gas chromatography/mass spectrometry of the pertrimethylsilyl derivatives after extraction two times with two volumes ethyl acetate (5) . Because of the poor extraction yield of of glyceric acid a quantitative determination was achieved by extracting the urine five times with four volumes of ethyl acetate, giving a reproducible recovery of 25%. Plasma glycerate was analyzed in the same manner. The lower detection limit of this technique was established to be 10 pmol/liter. Oxoacids and aldehydes such as glyceraldehyde were analyzed in the form of methoximes or ethoximes by capillary gas chromatography: prior to ethyl acetate extraction the sample was left to react with 4 mg methoxyamine HC1 or ethoxyamine HCl for each ml of urine at room temperature for 2 h. The absolute configuration of the urinary glyceric acid was established by capillary gas chromatographic separation of the 0-acetylated (-)-menthy1 esters, essentially as described previously (2) . The ethyl acetate extract was not purified further prior to the derivatization. D-and L-glyceric acids to be used as reference compounds were synthesized according to Wohl and Schellenberg (6) (J. P. Kamerling, laboratory for Organic Chemistry, State University, Utrecht). The patient's erythrocyte contents of intermediates of the glycolytic pathway and the activities of various glycolytic enzymes were measured by previously established techniques (7) .
Oral loading tests with L-serine (200 mg/kg), fructose (I g/kg), and dihydroxyacetone (1 g/kg) were performed after an overnight fast; the fasting state was subsequently maintained for 4 more h. Urine samples were collected 24 h prior to loading and in two 6-h and a 12-h portion after loading when possible. Venous plasma samples were taken at regular intervals starting at the moment of loading. During the in vivo studies the antiepileptic medication was continued. Fructose in plasma was analyzed by a colorimetric method using thiobarbituric acid (8) . It should be mentioned that additional in vivo studies were not allowed by the parents.
RESULTS
As part of the screening program for inherited metabolic disorders, urinary organic acids were analyzed. This showed, in addition to the multiple peaks due to valproate medication, a prominent peak in the position of glyceric acid. Its identity was confirmed by gas chromatography/mass spectrometry which showed the molecular mass to be 322. Major fragments were observed at m/z values of 307, 292, 205, and 189. As glyceric acid may occur in two forms, its absolute configuration was established after conversion of the substance present in the ethyl acetate extract into a diastereomer by reacting it with (-)-menthol and acetic anhydride. Capillary gas chromatography of the acetylated (-)-menthy1 esters showed the urinary glycerate to be exclusively in the D-form. Neither glyceraldehyde nor hydroxypyruvate could be detected in random urine samples by analyzing urinary 0x0-compounds as their methoxime-TMS or ethoxime-TMS derivatives. Urinary ~-glycerate levels in the present patient showed a considerable variation: values between 0.56 and 9.30 mmol/liter (or 0.57-17.06 mmol/g creatinine) were observed in periods when the patient was on a normal diet. Fasting plasma glycerate was 60 pmol/liter on two occasions; its concentration was too low to allow a determination of the absolute configuration.
The biochemical effects of the various oral loading tests with L-serine, fructose, and dihydroxyacetone are shown in Figures 1,  2 , and 3. It is evident that loading with L-serine, which can be thought to be a precursor of D-glycerate via the hydroxypyruvate pathway, had no effect on the excretion of D-glycerate (Fig. 1) . Neither hydroxypyruvate nor L-glycerate could be detected after serine loading. Loading with L-serine did not have an effect on plasma glycine; its concentration remained virtually unchanged at values between 357 and 401 pmol/liter. Serine showed the expected rise from 139 Fmol/liter to a peak of 467 pmol/liter after I h. Plasma glucose and lactate concentrations during this test were not recorded.
Fructose loading caused a sharp increase in both urinary and plasma glycerate. Urinary glycerate was as high as 68.5 mmol/ liter in the first 6 h after loading (Fig. 1) . The duration of the increase of the D-glycerate excretion was rather short; its concentration had already dropped to preloading values in the second 6-h urine sample after loading; neither glyceraldehyde nor hydroxypyruvate could be detected. It could be calculated that only 4.5% of the fructose intake was recovered as urinary glycerate. Plasma glycerate almost returned to the baseline level after 3 h (Fig. 2) . The disappearance of fructose from the plasma was normal: the peak plasma concentration of 0.7-0.9 mmol/liter at 30-60 min was comparable to that observed in control children after a similar oral load. Plasma glucose and lactate behaved similarly after an initial sharp increase they rapidly fell to preload levels. A healthy adult control who was loaded with 50 g fructose did not excrete glyceric acid.
The most impressive result was observed after loading with 1 g/kg dihydroxyacetone, which led to a peak urinary D-glycerate concentration of 156.9 mmol/liter (Fig. 1) . It could be calculated that 16.7 mmol of D-glycerate were excreted in the first 12 h after the load, representing 8% of the ingested dihydroxyacetone. During this test plasma glycerate levels were followed for 60 min. As soon as 30 min after the load a concentration of 2.1 mmol/ liter was observed, which did not show a tendency to decrease after 60 min (Fig. 3) . The plasma concentration of dihydroxyacetone paralleled that of D-glycerate, whereas the time course of the concentrations of glucose, lactate, and alanine was different. Plasma serine remained fairly stable during the test; concentrations between 180 and 240 pmol/liter were recorded (graph not shown). Careful analysis of urinary 0x0-compounds by gas chromatography/mass spectrometry of the corresponding methoximes or ethoximes revealed some unchanged dihydroxyacetone and a trace of glyceraldehyde in the first urine sample after loading. Hydroxypyruvate was not detected. Loading of a control child with an equivalent amount of dihydroxyacetone led to the excretion of only a trace (<20 pmol/liter) of glyceric acid. None of the loading tests led to adverse clinical reactions in the patient. Following these provocation tests the patient was put on a low fructose/saccharose diet in which fruits were omitted completely and vegetables and potatoes were restricted. She showed some clinical improvement according to the observations of her parents, in particular the frequency of the seizures seemed to decrease somewhat.
Biochemically the effect of the dietary fructose restriction was expressed in a lowering of the D-glycerate excretion; posttreatment urine concentrations of 0.33 and 0.48 mmol/liter were recorded. The assay of the activities of various glycolytic enzymes in erythrocytes showed only one abnormality: GAPD was rather low at 64 U/g Hb (controls 142-3 10). On a separate occasion 69 U/g Hb was found. All other enzymes, including triokinase, showed normal activities. One of the glycolytic intermediates, viz dihydroxyacetone phosphate, was present in an increased concentration; values of 34 nmol/ml erythrocytes (fasting) and 9 1 nmol/ml erythrocytes (nonfasting) were recorded. The control values are 12.1 +. 5 
.1 (SD).
Enzyme studies in other tissues or cells were not done; one of the reasons was that liver tissue was not available. Neither Dglycerate kinase nor D-glycerate dehydrogenase is expressed in human fibroblasts (K#lvraa S, personal communication) .
Biochemical investigations of the family members did not reveal abnormalities; both the father and the mother excreted no more than trace amounts of glyceric acid. A healthy sister of the patient, born in 1983 and a healthy brother, born in 1985, did not excrete measurable amounts of glycerate.
DISCUSSION
The present patient adds another one to the hitherto very small series of three D-glyceric acidemia patients. Clinically the patients can be divided into two categories: three with a severe encephalopathy including the present one versus the single patient described by Wadman et al. (2) who exhibited a moderate metabolic acidosis only. Both the Danish patient (1) and the French patient (3) were reported to have the clinical symptoms resembling nonketotic hyperglycinemia. However, these symptoms are rather nonspecific, especially in late onset patients. We therefore prefer not to compare our patient with hyperglycinemia patients. Although valproic acid [= di-(n-propyl) acetic acid] has been shown to interfere with various metabolic processes, we have never experienced abnormal glyceric aciduria due to valproate medication.
Not only is there a clinical difference between the two groups of patients, there also appears to be a biochemical difference. Both the present patient and the Danish patient react to fructose loading (4) by increasing their urinary D-glycerate excretion and Wadman's original patient was the only one to react to a serine challenge (2) . Although a defect at the molecular level has not been established in any of the patients, our knowledge about the human metabolism of serine and fructose could be combined with the available data to give a hypothesis.
Although not always unambiguously stated, serine metabolism seems to involve different pathways for synthesis and degradation. It is generally agreed that serine biosynthesis from carbohydrate proceeds via the so-called phosphorylated pathway as shown in Figure 4 (reaction 13). The latter reaction is of little or no importance in the human (10) . Evidence for the catabolism of serine via Dglycerate stems from the existence of patients (1 l ) with L-glyceric aciduria and a partial deficiency of D-glycerate dehydrogenase (enzyme 6), although the flux through this pathway should be small, in view of the low activities of D-glycerate kinase in human as compared to rat liver (12, 13) . The absence of L-glyceric acid excretion in patients with D-glyceric acidemia provides an indication that their D-glycerate dehydrogenase activity is normal. The metabolic effects of fructose and dihydroxyacetone in the present patient clearly distinguish her from those with previously discovered disorders of fructose metabolism such as fructosuria, hereditary fructose intolerance, and fructose-l,6-diphosphatase deficiency (14) . Nevertheless this patient is likely to suffer from a defect in the intermediary metabolism of fructose. The normal metabolism of fructose proceeds via fructose-1-phosphate to glyceraldehyde and dihydroxyacetone phosphate (Fig. 4) . Glyceraldehyde can be metabolized as follows: (a) reduction to glycerol (not shown in Fig. 4 ), (b) oxidation to D-glycerate catalyzed by aldehyde dehydrogenase (reaction 5), and (c) phosphorylation catalyzed by triokinase (reaction 3). It is generally agreed that the latter reaction is favored in human liver (1 5, 16) , followed by oxidation of the reaction product glyceraldehyde-3-phosphate to 3-phosphoglycerate. Thereafter our results from the fructose loading are not incompatible with a partial deficiency of triokinase or a KM-variant of this enzyme. A deficiency of triokinase would promote the conversion of glyceraldehyde to D-glycerate. As this D-glycerate apparently could not sufficiently be metabolized further, the logical conclusion would be that the capacity to metabolize D-glycerate with D-glycerate kinase was surpassed. This implies that liver and erythrocyte are different enzymes, the activity of the latter being entirely normal in the present patient. An enzyme anomaly even lower in the fructose catabolic pathway is considered to be less likely, as this pathway is shared by fructose and glucose, and the continuous high glucose turnover would lead to much higher D-glycerate excretions if this were the case. Dihydroxyacetone has to be very close to the primary defect as judged by the result of the loading test. Its metabolic fate is phosphorylation by triokinase or by glycerol kinase to dihydroxyacetone phosphate, the latter enzyme has a much higher K M for dihydroxyacetone (17) . The phosphorylated product is then isomerized to glyceraldehyde-3-phosphate (Fig. 4, reaction 8) . Mal- functioning of triokinase will lead to accumulation of the ingested dihydroxyacetone which could possibly be converted to D-glycerate by a sequence of reactions: (i) oxidation to hydroxypyruvaldehyde by alcohol dehydrogenase followed by (ii) oxidation to hydroxypyruvate by aldehyde dehydrogenase and (iii) conversion to D-glycerate by D-glycerate dehydrogenase (Fig. 4, reaction  6 ). The limited capacity of the liver to phosphorylate D-glycerate would then cause an excessive D-glyceric aciduria. The enzyme defect in this patient (presumably triokinase) has to be partial because only a small portion of the loads was excreted in the form of D-glycerate.
To the best of our knowledge a deficiency of triokinase has not been described before, hence it is not known if such a deficiency could result in a distinct clinical picture.
Our patient did not excrete abnormal amounts of short-chain acylglycines as was described in the Danish patient (1 8). In our opinion there is no relation between the abnormality leading to D-glyceric aciduria and the inability to metabolize short-chain fatty acids. Although D-glycenc aciduria seems to be extremely rare (this patient is only the fourth one reported) the assumption can be made that more patients can be found. We have shown that there may be a considerable variation of the daily D-glycerate output and it can thus be advocated to perform provocative loading tests with fructose and dihydroxyacetone in patients who excrete only small amounts of glyceric acid.
